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ABSTRACT. The Mg2+-dependent salicylate synthase (MbtI) from Mycobacterium tuberculosis 
is a key enzyme involved in the biosynthesis of siderophores. Because iron is essential for the 
survival and pathogenicity of the microorganism, this protein constitutes an attractive target for 
antitubercular therapy, also considering the absence of homologous enzymes in mammals. An 
extension of the SAR of our furan-based candidates allowed us to disclose the most potent 
competitive inhibitor known to date (10, Ki = 4 μM), which also proved effective on 
mycobacterial cultures. By structural studies, we characterized its unexpected Mg2+-independent 
binding mode. We also investigated the role of the Mg2+ cofactor in catalysis, analyzing the first 
crystal structure of the MbtI-Mg2+-salicylate ternary complex. Overall, these results pave the way 
for the development of novel antituberculars through the rational design of improved MbtI 
inhibitors. 
INTRODUCTION 
Nowadays, tuberculosis (TB) ranks among the top ten causes of death worldwide; therefore, 
the development of new scaffolds is imperative to sustain the drug pipeline, considering the 
issues of the available antitubercular therapies and the increasing emergence of resistant 
infections.1 The salicylate synthase (MbtI) from Mycobacterium tuberculosis (Mtb, the 
etiological agent of TB) is the first enzyme involved in the biosynthesis of mycobactins. These 
small-molecule siderophores are capable of chelating iron, a key cofactor involved in several 
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mycobacterium-specific biological processes. MbtI has been structurally and biochemically 
characterized,2 it is essential for the survival of Mtb under iron-deficient conditions,3 and, as 
such, it has been identified as a promising therapeutic target.4 
MbtI belongs to the group of the structurally homologous Mg2+-dependent menaquinone, 
siderophore and tryptophan (MST) enzymes, which transform chorismate by rearrangement, to 
generate precursor molecules for the respective biosynthetic pathways.5,6 In this context, MbtI 
catalyzes the two-step conversion of chorismate to salicylate, via isochorismate as intermediate, 
performing an isomerase activity followed by a lyase activity (Figure 1).4 
 
Figure 1. Reactions catalyzed by MbtI. 
Several strategies have been adopted for the discovery of MbtI inhibitors. In particular, 
dicarboxylate substrate analogs (chorismate and isochorismate), transition state analogs and 
compounds originated from HTS have been identified.7–10 However, these compounds, albeit 
active against the isolated enzyme, show modest effects on the whole mycobacterial cell.7–10 
Notably, Methyl-AMT (IC50 = 11.6 μM), the best MbtI inhibitor discovered to date not 
belonging to our furan-based class, exhibited a poor minimum inhibitory concentration (MIC50 ≥ 
1 mM), which remained weak (MIC50 = 792 μM) for its more lipophilic dimethyl ester analog as 
well.4 
Therefore, in order to find improved MbtI inhibitors, we followed an in silico screening 
approach, which led to the identification of a new hit.11 While exploring the chemical space 
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around this compound in the frame of a thorough structure-activity relationship (SAR) study, we 
discovered two effective derivatives, I and II (Figure 2), which are, to our knowledge, the most 
potent MbtI inhibitors reported to date (IC50 = 7.6 ± 1.6 μM and 13.1 ± 2.0 μM, respectively). 
This strong inhibition of MbtI is correlated to a lethal effect on Mtb cultures (MIC99 = 156 μM 
and 250 μM, respectively).11,12 Furthermore, the Universal CAS assay confirmed the connection 
between the antimycobacterial effect of these compounds and the disruption of mycobactin 
biosynthesis, thus highlighting the importance of this pathway as a target for the development of 
therapeutic interventions. Moreover, we demonstrated the possibility of removing one of the 
carboxylic groups of Methyl-AMT, without causing a loss in the inhibitory potency and 
allowing, at the same time, a better permeability through the cell wall of Mtb.11,12 
 
Figure 2. Chemical structures of compounds I and II. 
Despite the promising results obtained in the inhibition of this target,4 its mechanism of action 
is still poorly understood and not supported by conclusive experimental data. In particular, a 
robust definition of the role of Mg2+ in the interaction between MbtI and inhibitors is still 
lacking. It has been reported that the affinity of the MST enzymes EntC, PchA and Irp9 for 
ligands is much higher than that for the metal ion, so the driving element of the catalytic reaction 
is the binding of the substrate, followed by interaction with the cofactor.6 After the conversion of 
chorismate to isochorismate, a sudden change in the affinity for the metal occurs: Mg2+ is 
retained by MST enzymes with an extremely high affinity, promoting the subsequent reaction 
which quickly leads to the formation of salicylate.6 
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Stimulated by these findings, we started to consider if I and II may participate in the inhibition 
mechanism by occupying the active site of the free MbtI before the intervention of the Mg2+ ion, 
thus blocking the isomerase activity. In this work, we provide experimental data to explain the 
role of Mg2+ on the activity and inhibition of MbtI. Firstly, we expanded our library of furan-
based compounds, designing and synthesizing new meta-derivatives. Among them, the most 
potent inhibitor identified so far (the m-cyano compound 10, Table 1) was selected as the most 
suitable candidate to deepen our investigations. The determination of its activity, performed at 
increasing concentrations of Mg2+, showed that the metal did not influence the binding of the 
compound to the target. Then, we updated our computational model, taking into account the 
Mg2+-independent binding mode, which allowed us to identify a previously unconsidered key 
role of some residues. This hypothetical pose was supported by the obtainment of the 
crystallographic complex of MbtI with 10, which is here described. As a proof of principle, we 
also solved a crystal structure of the enzyme in complex with Mg2+, obtained at saturating 
concentrations of the metal. Moreover, the MbtI-Mg2+ crystal structure evidenced the presence of 
salicylate, the product of the enzymatic reaction. Notably, the presence and the interaction 
pattern of salicylate at the active site confirmed the hypothesized catalytic mechanism of MbtI, 
previously inferred by similarity to other MST enzymes. 
RESULTS AND DISCUSSION 
Synthesis and SAR of compounds 1-10 
Inspired by the encouraging activity of our leads I and II,11,12 we decided to further explore the 
phenyl-furan scaffold. In particular, with the aim of obtaining additional SAR data, we focused 
on exploring the meta position of the phenyl ring using substituents endowed with different 
stereoelectronic properties, many of which already employed in our previous studies in which the 
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ortho and para positions of the phenyl ring were mainly substituted. Compound 1, bearing only 
one CF3 at position 3, was purchased from a commercial source, while 2-10 were synthesized. 
Compounds 2-4,6-10 were synthesized by a Suzuki-Miyaura reaction,11 either between methyl 
5-bromofuran-2-carboxylate and the suitable boronic acid, or between (5-
(methoxycarbonyl)furan-2-yl)boronic acid and the appropriate bromo-derivative. The so-
obtained esters were hydrolyzed in basic-conditions to yield the free carboxylic acids (Scheme 
1). Finally, compound 5 was synthesized from 5-(3-nitrophenyl)furan-2-carboxylate (23) through 
the reduction of its nitro group with tin(II) chloride,13 followed by the hydrolysis of the ester 
function (see Scheme S1 in Supporting Information, SI). 
Scheme 1. Synthesis of compounds 2-4, 6-10. 
 
Reagents and conditions: a) conc. H2SO4, MeOH, reflux, 24 h; b) Pd(PPh3)2Cl2, 2M Na2CO3, 
1,4-dioxane, 90 °C, overnight, N2; c) NaOH, EtOH/THF 1:1, reflux, 5 h or LiOH∙H2O, THF/H2O 
1:1, 20 °C, 2 h. d) 1. bis[2-(N,N-dimethylamino)ethyl] ether, 2M i-PrMgCl, THF, 20 min. 10-15 
°C – 30 min. r.t., N2; 2. B(OCH3)3, 0 °C, 10 min., N2; e) Pd(PPh3)2Cl2, 2M Na2CO3, 1,4-dioxane, 
60 °C, 90 min., MW, N2. 
The activity of compounds 1-10 was tested against recombinant MbtI (Table 1), prepared and 
assayed as previously reported.12 Compound 1 showed a promising activity, while the 
 7 
replacement with a halogen (2) or with electron-donating functions like the hydroxyl (3), methyl 
(4) or amino (5) groups abolished or significantly weakened the activity. The insertion of a 
strong electron-withdrawing group capable of forming a localized negative charge, like the NO2 
function, previously published (inhibitory activity:  ̴ 50%, at a concentration of 100 μM),11 did 
not lead to an improvement of the activity. Conversely, the amide group of 6 allowed for a 
significant enhancement of the inhibition, as shown by the IC50 value of 31 µM. While the 
methylation of the amide in compound 7 led to a strong decrement of the activity, the 
substitution of the amide with classical bioisosteres (sulfonamide, 8; carboxylic acid, 9) allowed 
for a retention of the inhibitory effect. Interestingly, the substitution with a nitrile in 10 afforded 
the best compound of the series, characterized by an IC50 value of about 6 µM; this inhibitor 
proved to be slightly better than the previous candidates I and II, thus becoming our improved 
lead compound. 
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Table 1. m-Substituted derivatives 1-10. Inhibitory effect is expressed as percentage of residual 
enzymatic activity (at 100 μM ligand concentration) for all compounds and Half-Maximal 
Inhibitory Concentrations (IC50, μM) only for the most active candidates (residual activity ≤ 
25%). 
 
Code R % Residual activity IC50 (μM) 
1 3-CF3 42.0 ± 6.3 - 
2 3-Cl 101.6 ± 17.8 - 
3 3-OH 70.4 ± 21.8 - 
4 3-CH3 103.9 ± 4.8 - 
5 3-NH2 65.8 ± 9.6 - 
6 3-CONH2 20.9 ± 4.3 31.4 ± 10.3 
7 3-CONHCH3 84.0 ± 9.1 - 
8 3-SO2NH2 28.6 ± 6.8 - 
9 3-COOH 27.2 ± 4.5 - 
10 3-CN 3.1 ± 1.0 6.3 ± 0.9 
 
Biological assays 
Compound 10 underwent an in-depth biological evaluation (Figure 3), aimed at characterizing 
its activity on MbtI and confirming the correlation with a lethal effect on the whole 
mycobacterial cell. A kinetic analysis confirmed 10 as a competitive inhibitor of MbtI, with a Ki 
value of 4.2 ± 0.8 M (Figure 3A). Additional tests were performed to ensure that it was not a 
PAIN:14 the addition of BSA and Triton X-100 did not influence the IC50 (6.1 ± 0.9 μM and 5.8 
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± 1.2 μM, respectively), suggesting that it does not form aggregates with the target. Similarly, 
the addition of DTT did not impact on the activity of 10 (IC50 7.2 ± 1.1 μM), showing that the 
ligand does not interact with the cysteine residues of the protein (Figure 3B). The 
antimycobacterial activity of 10 was tested on M. tuberculosis H37Rv, providing an MIC99 value 
(250 µM) similar to those of the previous inhibitors I and II.11 Moreover, to ascertain that the 
effects of the compound were due to mycobactin inhibition, 10 was assayed against the non-
pathogenic M. bovis BCG strain, whose siderophores closely resemble Mtb mycobactins,15 in 
iron-limiting conditions, using the chelated Sauton’s medium. The compound showed an MIC99 
value of 250 μM, and the Universal CAS liquid assay and quantification of the mycobactins16 in 
treated cultures demonstrated that siderophore concentration decreased at higher concentrations 
of the compound (Figure 3C and 3D). This observation confirmed that the inhibitory effect 
towards mycobacterial growth was due to mycobactin biosynthesis inhibition. Finally, 10 was 
screened, following the previously published procedure,12 against human MRC-5 fibroblasts to 
evaluate its cytotoxicity, revealing an IC50 > 100 μM, thus indicating a low level of toxicity. 
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Figure 3. Global reciprocal plot of data from MbtI steady-state kinetics analysis towards 
chorismic acid, at different concentrations of 10 (A). IC50 plot of 10 in the presence of BSA 
(red), Triton X-100 (green) and DTT (blue) (B). Universal CAS assay performed on M. bovis 
BCG, grown at different concentrations of 10 (C). Determination of mycobactins in the 
abovementioned cells. Bars represent mean and standard deviations of three independent 
experiments (D). 
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Investigations around the Mg2+ ion 
Meneely et al.6 demonstrated that, in iron-limiting conditions, the affinity of the MST enzymes 
EntC, PchA and Irp9 for Mg2+ is rather low; hence, the ligand is the first driving element of the 
catalytic reaction. Subsequently, the binding of the Mg2+ caps the active site, thus promoting the 
initiation of the biosynthetic process. After the conversion of chorismate to isochorismate, a 
sudden change in the affinity for the metal occurs: the enzyme tightly binds Mg2+, preventing the 
release of the intermediate and allowing the reaction to quickly evolve towards the formation of 
salicylate.6 
According to this theory, a ligand endowed with inhibitory properties should therefore be able 
to bind to the active site of an MST enzyme, without having to interact with or, much less, be 
oriented by the Mg2+ ion. On these bases, we undertook an investigation to verify if such a 
deduction could be applied to MbtI and to our compounds. Considering that the presence of 
Mg2+ has been one of the assumptions of most computational studies regarding MbtI, including 
ours, we realized that unravelling the binding mechanism of our inhibitors would have a 
particular significance. In order to ascertain the likelihood of a Mg2+-independent binding mode 
for our compounds, docking experiments, combined with molecular dynamics (MD) simulations, 
were carried out. The predicted dispositions of 10 into the catalytic site of MbtI was calculated 
by docking in the absence of the Mg2+ ion and then refined through 100 ns of MD simulation 
with explicit water molecules (see Experimental Section for details). The results of these studies 
are shown in Figure 4, which represents the minimized average structures of 10 within the MbtI 
binding site. The carboxylic group of the ligand shows interactions with the hydroxyl group of 
Tyr385 and the backbone nitrogen of Arg405. The furan oxygen forms a H-bond with Lys438, 
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whereas the benzonitrile fragment shows lipophilic interactions with Ile207, Leu268, Thr361 and 
an H-bond with Lys205. 
 
Figure 4. Minimized average structure of 10 within MbtI binding site (PDB ID 3VEH) in 
absence of the Mg2+ ion. 
Hence, our modeling approach showed that a Mg2+-independent binding mode was indeed 
possible, although the exact pose of the ligand could hardly be predicted by a docking/MD 
simulation study. Therefore, further experimental studies were carried out to characterize the 
binding mode of our inhibitor. 
Biochemical investigations on 10 
Firstly, we acquired further biochemical data on 10, testing its activity at different 
concentrations of Mg2+, with the aim of defining the role of the cofactor in the interaction 
between MbtI and the inhibitor. With this strategy, we envisaged that we would observe 
differences in the inhibitory effect of our ligand in the presence of varying amounts of Mg2+, if 
the ion were necessary for its binding and correct orientation in the active site. As expected, MbtI 
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was found to be completely inactive in the absence of its cofactor, reaching the maximal activity 
only at 2 mM MgCl2. This result confirmed that the ion is essential for enzymatic activity, 
although the affinity seems rather moderate. Despite Ferrer et al.17,18 reported on the ability of 
MbtI to act as chorismate mutase in the absence of the metal, leading to the synthesis of 
prephenate, our data corroborate the hypothesis formulated by Ziebart and Toney19 that such 
activity is likely due to a faulty purification of the enzyme. Moreover, the use of increasing 
concentrations of Mg2+ (> 50 mM) showed inhibitory effects, as the enzyme activity significantly 
decreased (Figure 5). Conversely, the enzyme no significant decrease in specific activity when 
assayed at concentration of KCl up to 500 mM, confirming that inhibition is specific to Mg2+, 
and not due to increased ionic strength. 
The determination of the activity of 10, performed at different concentrations of Mg2+, showed 
that the metal did not strongly influence the binding of the compound to the target. However, in 
the presence of very high Mg2+ concentrations, the performance of 10 was slightly reduced. This 
observation further supported the hypothesis that at moderate concentrations of Mg2+, the ligand 
preferentially binds (and inhibits) MbtI, while the metal has a low affinity for the enzyme. At 
high Mg2+ concentrations, our data suggest that the ion nevertheless binds to the active site, 
occluding the catalytic region and blocking the access of the inhibitor. These data might also 
indicate that our compound could prevent the binding of Mg2+ in a competitive fashion, 
becoming slightly less effective when the concentration of the metal reaches the higher 
millimolar range (Figure 5). 
 14 
 
Figure 5. MbtI enzyme activity as a function of [Mg2+] (A). Profiles of the IC50 of 10, obtained 
at different concentrations of Mg2+ (B). 
Synthesis and activity of a probe (11) 
To date, most MbtI inhibitors reported in the literature, including our candidates, share a 
common carboxylate motif that is supposedly responsible for functional sequestration of the 
metal ion within the active site.20 However, according to our hypothesis, this interaction may not 
be necessary neither for the binding of the ligand, nor for the resulting inhibitory effect. In order 
to further verify this theory, we designed and synthesized a probe molecule, introducing a 
chemical modification on 10. The Mg2+ ion is characterized by a small ionic radius, high charge 
density and tendency to bind water molecules in the inner coordination sphere, rather than 
bulkier ligands. Being a “hard” ion, it prefers to bind “hard” oxygen-containing ligands, such as 
carbonyls, carboxylates, phosphates, hydroxyls, and water.21 Therefore, the carboxylate 
pharmacophore motif was converted to an amide function, affording the analog 11 (see Scheme 
S2 in SI). Its docking into MbtI in the absence of Mg2+ suggested that a very similar binding 
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mode to that proposed for 10 was likely (Figure S62). The biological tests on compound 11 
confirmed a very good inhibitory activity (IC50 = 17.3 ± 1.9 μM), thus supporting our hypothesis 
that the metal chelation should not be considered an essential pharmacophore feature to develop 
inhibitors of MbtI. 
Structure of MbtI in complex with 10 
In the context of our attempts to elucidate the structure of complexes between MbtI and 5-
phenylfuran-2-carboxylic acid-based inhibitors, we obtained cocrystals with the lead compound 
10: structural data and refinement statistics are summarized in Table 2. 
These experiments were undertaken to definitively characterize the binding mode of our 
candidates, thus providing a reliable means to verify the results of the computational simulations, 
as well as our previous observations. Furthermore, considering both the limited size of the 
compounds and the high plasticity of the active site, we were convinced that structural studies 
would assume a particular significance in the identification of the key enzyme-inhibitor 
interactions.12 
Among the 3D structures of MbtI available in the PDB, two different conformations have been 
reported, which have been described as “open” (e.g. PDB ID 2G5F)2 and “closed” (e.g. PDB ID 
3LOG)7, depending on the relative position of two mobile loops with respect to the active site. In 
the closed form, the flexible sequences (residues 268-293 and 324-336)20 are bent over the 
binding pocket, while in the open form they are tilted upward. A comparative analysis of 
previously published structures allowed us to identify the intermolecular bonds responsible for 
this conformational shift. In particular, the closed state seems to be determined by the formation 
of a H-bond between a suitable moiety of the ligand and the NH of Gly270 and/or the hydroxyl 
group of Thr271: these contacts effectively drag the first mobile loop towards the active site. In 
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turn, Thr271 establishes a bond with His334, thus pulling the second mobile loop in the same 
direction. The link between the flexible regions is further stabilized by additional interactions, 
formed by adjacent amino acids. Overall, this movement determines the capping of the active 
site. The chemical entity responsible for the interaction with Gly270 or Thr271 is a carbonate 
anion (or an ordered water molecule) in 3LOG, and a carboxyl group in PDB IDs 3ST6 and 
3VEH (chains A, B, C). Interestingly, in PDB IDs 3RV7, 3RV8, 3RV9, the absence of this H-
bond induces an open conformation, despite the orientation of the ligands does not differ 
significantly compared to the one observed in 3VEH. In chain D of 3VEH, the increased distance 
between the COOH and Thr271 (3.21 Å vs 2.70-2.89 Å) determines an intermediate 
conformation. Another intermediate, but overall open state can be observed in 3RV7 chain B, in 
which a contact between Thr271 and Ser331 induces a slightly more closed configuration 
compared to the other chains. The peculiar binding mode of the bulkier inhibitor of PDB ID 
3RV6 determines an unprecedented conformation, in which the opening of the mobile loops is 
characterized by a particularly wide angle. Notably, these mobile regions are characterized by 
high B-factors and partial lack of supporting electron density, especially when the conformation 
is open, despite some chains show stabilized conformations, mostly in the 324-336 loop, due to 
different crystal packing interactions involving these regions. 
In the complex MbtI-10, the enzyme conformation can be defined as an open state for the 
ensemble of the four molecules in the ASU, despite the partially incomplete electron density of 
the mobile loops (unresolved regions for chain A: 271-276; chain B: 270-290 and 328-334; chain 
C: 275-282; chain D: 274-277). The adoption of this conformation is due to the fact that 10 does 
not possess a suitable functional group in the correct orientation to establish a H-bond with 
Gly270 or Thr271. Consequently, the arrangement of the flexible loops of MbtI-10 is similar to 
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that of 2G5F, 3RV7, 3RV8, and 3RV9, with root-mean-square deviations in the range 1-4 Å 
(calculated for residues 325-335). 
An electron density compatible with the presence of the ligand is detectable in all four chains 
of the ASU, with the furan-2-carboxylic acid region always well-defined, and weaker electron 
density for the phenyl portion. The analysis of the binding mode of the compound revealed the 
presence of H-bonds between its carboxylic group and Tyr385, Arg405, and an ordered water 
molecule; the oxygen of the furan interacts with Arg405, while the phenyl ring forms a cation-π 
interaction with Lys438 and a Van der Waals contact with Thr361. Finally, the cyano group 
forms a H-bond with Lys205, a key amino acid involved in the first step of the catalytic reaction 
(Figure 6). This residue is likely responsible for the activation of a water molecule for 
nucleophilic attack (SN2”) on C2 of chorismate, which leads to the release of the hydroxyl group 
at position 4, after its protonation mediated by Glu252, thereby affording isochorismate.22 One 
may speculate that the absence of an interaction with the pivotal Lys205 in isochorismate-based 
derivatives accounts for their slightly weaker inhibitory activity with respect to 10. The 
superposition of MbtI-10 with 3RV7 (Figure S54) shows that the arrangement of the amino acid 
side chains around the ligands is similar, with the aromatic carboxylic group of the AMT 
derivative occupying the same position as the acid moiety of 10. The most significant difference 
is represented by the ability of the nitrile group of 10 to form a H-bond with Lys205, thereby 
hindering its physiological functions. 
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Figure 6. Ribbon diagram of the MbtI-10 structure (PDB ID 6ZA4): the interactions of the 
ligand with the side chains (in sticks) and the water molecules (blue spheres) are represented as 
dashed lines. The blue mesh represents the electron density around the ligand (contoured at 1σ). 
Despite our experiments were carried out in the presence or in the absence of Mg2+ in the 
crystallization buffer (2-5 mM of different Mg2+ salts), we never observed any bound Mg2+ in the 
MbtI-10 cocrystal structure. The orientation of the ligand is substantially in agreement with the 
predicted binding mode of 10 in the absence of Mg2+, as shown by the overlay of the two models 
(Figure S55). The binding poses in the two complexes exhibit a root-mean-square deviation of 
1.6 Å and similar interactions. The main differences are related to the orientation of the side 
chain of Arg405, which was not predicted to interact with the ligand, as well as the side chains of 
Thr271 and His334, which are shifted away from the binding site. As previously mentioned, the 
absence of interactions between the ligand with the amide group of Gly270 or the hydroxyl 
group of Thr271 seems to favor the outward movement of the backbone in the two mobile loops, 
thereby leading to an open conformation. Such shift could hardly be predicted by computational 
simulations, as those were based on a closed form of the enzyme. As for Arg405, the analysis of 
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electron density indicates a high flexibility of its side chain, which is otherwise modeled, where 
supporting density is present, as different rotamers. 
Structure of MbtI with the Mg2+ ion 
Although the role of the Mg2+ cofactor in the catalytic activity of MbtI has been the subject of 
a number of publications,4 its role remains elusive. Our numerous attempts to obtain a structure 
of MbtI in ternary complex with 10 and Mg2+ failed, invariably leading to the cocrystal described 
above. Notably, the only available structure of MbtI showing a bound Mg2+ ion was obtained by 
Chi and co-workers (3RV6).20 However, as stated by the authors, its binding mode under those 
conditions may not necessarily reproduce the physiological situation: the ion was found to be 
hexacoordinated by water molecules, interacting with the enzyme and the inhibitor only through 
the surrounding waters, inconsistently with both its supposed role in catalysis18 and the authors’ 
predicted binding mode. Therefore, we decided to further pursue the investigation of the binding 
and coordination of Mg2+ into the active site of MbtI, in order to clarify its role in the enzymatic 
mechanism. 
Considering the inherent difficulty in obtaining MbtI-Mg2+ cocrystals, as well as the results of 
our biochemical assays, we hypothesized that we could compensate for the rather low affinity of 
MbtI for its cofactor by using saturating concentrations of Mg2+. Interestingly, 2.1 Å resolution 
data were collected from a non-isomorphous crystal grown under these conditions (Table 2). 
The crystal structure derived from these data presents four molecules in the ASU, with a well-
defined electron density in all regions, including the previously observed mobile loops that are 
now stabilized into a closed conformation, superimposable with the one observed in 3LOG or 
3ST6.7,20 The analysis of the active site evidenced electron density fully consistent with the 
presence of a Mg2+ ion, though its coordination sphere is slightly different in the various chains. 
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In chain A (Figure S56), the Mg2+ interacts with the oxygen of Gly421, with four ordered water 
molecules, and with a sulfate anion. Through two of the water molecules, it also contacts Glu431 
and Glu434. Chain C does not show the presence of the ion; in its absence, Glu431 binds a water 
molecule and there is no clear electron density for the side chain of Glu434. The coordination 
pattern of Mg2+ in chains B and D is analogous (Figure 7): the ion could be modeled as directly 
interacting with Glu297, Glu434, and two ordered water molecules, which in turn make H-bonds 
to Glu294 and Glu431. In addition to that, the metal forms a strong interaction with another 
molecule, which, by analogy with the crystal structure of Irp9 from Yersinia enterocolitica (PDB 
ID 2FN1), could be identified and modeled as a salicylate.23 Supporting density for the bound 
catalytic product could be identified in two protein chains over four, where the pose of the 
refined ligand was perfectly superimposable to that of 2FN1 (Figure S57). The salicylate 
coordinates the Mg2+ ion with its carboxylic moiety, which also forms additional H-bonds with 
the peptide backbone through Gly270 and Gly421, and with the side chain of Thr271. The 
hydroxyl group and the phenyl ring do not seem to form significant interactions. As previously 
noted, the bond between the carboxylic function and Gly270-Thr271 is responsible for the 
adoption of the closed conformation (Figure 8). The comparison of this structure with MbtI-10 
and 3RV7 showed a moderate rearrangement of the residues in the active site (Figure S58). Both 
the side chains of the interacting amino acids and some portions of the main chain backbone 
(Gly270) are tightened around the ion and salicylate, narrowing the binding pocket. The 
orientation of the salicylate is almost orthogonal to the plane formed by the rings of the 
inhibitors. Therefore, the aromatic carboxylic groups of the ligands and the carboxylate of the 
natural product do not occupy the same position: instead, the acidic moiety of the inhibitors is 
here replaced by a sulfate anion. Conversely, the aliphatic carboxylic function in 3RV7 may be 
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oriented towards the ion by rotation around the ether bond. The superposition of our Mg2+-bound 
structure with the closed structures 3VEH and 3ST6 showed a much similar arrangement of the 
residues in the binding pocket, with the exception of some amino acids involved in the binding 
of Mg2+, which are tilted away in the literature structures (Figure S59). Moreover, while the 
orientation of the compound in 3VEH is comparable to that of 3RV7, the position of the 
aromatic analogue of isochorismate in 3ST6 is overturned, with the aromatic portion occupying 
roughly the same position as the salicylate. This is the only AMT derivative which exhibits such 
an orientation. As mentioned above, the side chain of Arg405 also shows deviations due to its 
flexibility. 
 
Figure 7. Ribbon diagram of the MbtI-Mg2+ structure (PDB ID 6ZA5), focused on the active site 
of chain D. The interactions of the ligands with the side chains (in sticks), the Mg2+ ion (light 
blue sphere) and the water molecules (blue spheres) are represented as dashed lines. The blue 
mesh represents the electron density around the ligand (contoured at 1σ). 
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Figure 8. Comparison of surface of MbtI-10 (left, PDB ID 6ZA4) and MbtI-Mg2+(right, PDB ID 
6ZA5), showing the movement of the mobile loops (in green, only partially traced in MbtI-10 
due to the lack of supporting electron density). The active site accessibility determines the 
conformational state of the enzyme (open, in MbtI-10, vs. closed in MbtI-Mg2+). The blue mesh 
represents the electron density around active site ligands (contoured at 1σ); the side chains of the 
interacting amino acids are in sticks. 
The presence of bound salicylate in the structure is remarkable, especially considering that the 
natural substrate was not added to the crystallization solution. To confirm the presence of a 
salicylate molecule bound to the protein, MbtI (25 mg/mL) was heat-denatured to release any 
bound compound and centrifuged; the resulting supernatant was subjected to UPLH-MS 
analysis. As shown in Figure S63, a peak corresponding to that of the salicylic acid was detected 
in the supernatant of the treated MbtI, and not in controls. This finding suggests that the enzyme 
is active in the heterologous expression host (E. coli) and that either chorismate or salicylate, 
both of which are known to be intermediates in E. coli aromatic biosynthetic pathways, is co-
purified with the protein. It is worth to note that the first described crystal structure of MbtI 
(2G5F), also reportedly copurified from E. coli, showed the presence of pyruvate in the active 
site, which thus prompted the authors to classify the enzyme as a salicylate synthase.2 
Unsurprisingly, the position that was occupied by the pyruvate is here taken by a sulfate ion, 
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provided in the crystallization solution as the Mg2+ counterion. At increasing MgCl2 
concentrations the enzyme catalytic turnover is significantly reduced, strongly supporting the 
notion that high Mg2+ concentrations stabilize the closed conformation of the active site, 
preventing the loss of salicylate from the active site. Besides, the direct salicylate-Mg2+ 
interaction, shown here for the first time for MbtI, is consistent with biochemical observations on 
the role of Mg2+ by Meneely et al.6 
Furthermore, indirect confirmation of the binding position of Mg2+ in the active site of MbtI 
was obtained from another structure, solved from crystals grown in the presence of chorismate in 
its commercially available Ba2+ salt (Table 2). Despite no evidence of bound chorismate was 
found from the analysis of the electron density maps, a bound Ba2+ ion was identified (Figure 
S60). This divalent ion roughly occupies the same position of Mg2+ (Figure S61), further 
confirming the presence of a metal binding site. Ba2+ forms a similar pattern of interactions with 
the surrounding residues, with slight modifications due to its different steric hindrance. 
Moreover, as in the Mg2+-bound structure, the enzyme exhibits the same closed conformation: in 
this case, the H-bond with Thr271 is established by on oxygen of a phosphate anion, originating 
from the crystallization condition. 
CONCLUSIONS 
In this work, we report the discovery of a new pharmacophore model based on the crystal 
structure of Mycobacterium tuberculosis salicylate synthase (MbtI) complexed with 10, the most 
potent inhibitor discovered to date, also active against isolated mycobacterial cells. Our 
experiments proved the connection between its antimycobacterial effect and the disruption of 
mycobactin biosynthesis, confirming the importance of this pathway as a target for novel anti-TB 
therapies. The MbtI-10 structure highlighted a new mode of ligand-protein interaction in which 
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the binding of the ion is not a key feature for the development of improved inhibitors. Moreover, 
the co-crystal structure highlighted the importance of fundamental residues for the binding of the 
ligand, such as Thr361, Tyr385, Arg405, Lys438, and in particular of Lys205, a key amino acid 
involved in the first step of the catalytic reaction. These findings constitute the basis for the 
development of a novel pharmacophore model for MbtI ligands, which could be profitably 
employed in virtual screening protocols aimed at the identification of structurally novel 
inhibitors and in lead optimization campaigns focused on the development of more potent 
analogs of compound 10. 
In addition, the X-ray structure of MbtI complexed with Mg2+ is consistent with the proposed 
mechanism of the enzyme, and, most notably, the role of the Mg2+ cofactor. The crystal structure 
of the ternary complex of MbtI with Mg2+ and salicylate shows the product of the catalytic 
reaction chelating the metal ion with its carboxylic moiety, and forming additional H-bonds with 
Gly270, Gly421, and Thr271. Observing such a conformation in this ternary complex is not 
surprising when high concentrations of Mg2+ are present; consistently with previous hypothesis 
and biochemical data, the bound Mg2+ ion stabilizes the enzyme in a close conformation, which 
in turn prevents the loss of salicylate from the active site. 
These findings contribute to fill the gap in the understanding of the kinetic and chemical 
mechanisms of this enzyme, supporting the development of high affinity inhibitors. Given the 
structural similarity between MbtI and other MST enzymes, designing new antimicrobials 
endowed with a multi-target activity is now a foreseeable scenario. 
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EXPERIMENTAL SECTION 
Chemistry 
All starting materials, chemicals and solvents were purchased from commercial suppliers 
(Sigma-Aldrich, St. Louis, MI, USA; FluoroChem, Hadfield, UK; Carlo Erba, Cornaredo, Italy) 
and used as received. Anhydrous solvents were utilized without further drying. Aluminum-
backed Silica Gel 60 plates (0.2 mm; Merck, Darmstadt, Germany) were used for analytical thin-
layer chromatography (TLC), to follow the course of the reactions. Microwave-assisted reactions 
were carried out with a Biotage® Initiator Classic (Biotage, Uppsala, Sweden). Silica gel 60 (40–
63 μm; Merck) was used for the purification of intermediates and final compounds, through flash 
column chromatography. Melting points were determined in open capillary tubes with a Stuart 
SMP30 Melting Point Apparatus (Cole-Parmer Stuart, Stone, UK). All tested compounds were 
characterized by means of 1H NMR, 13C NMR, FT-IR, HRMS. 1H and 13C NMR spectra were 
acquired at ambient temperature with a Varian Oxford 300 MHz instrument (Varian, Palo Alto, 
CA, USA), operating at 300 MHz for 1H and 75 MHz for 13C. Chemical shifts are expressed in 
ppm (δ) from tetramethylsilane resonance in the indicated solvent (TMS: δ = 0.0 ppm), while J-
couplings are given in Hertz. The APT sequence was used when deemed necessary. The 2D-
NOESY sequence was employed to unambiguously assign the hydrogen signals, when 
appropriate; this experiment was performed on a Bruker Avance 300 MHz instrument (Bruker, 
Billerica, MA, USA). IR spectra were acquired with a Perkin Elmer Spectrum One FT-IR 
(Perkin Elmer, Waltham, MA, USA), in a spectral region between 4000 and 450 cm-1 and 
analyzed by transmittance technique with 32 scansions and 4 cm-1 resolution. Solid samples were 
mixed in a mortar with KBr (1:100) and pressed to small tablets, using a hydraulic press (14 
tons). The purity of the final compounds was assessed by means of LC-High-Resolution Mass 
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Spectrometry (Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer; Thermo 
Fischer, Waltham, MA, USA) and was ≥ 95%. 
Compound 1 was purchased from Sigma-Aldrich at the highest purity level available (≥ 95%) 
and tested as received. 
General Procedure A. Procedure A1. The appropriate methyl ester derivative (1 mmol) was 
dissolved in a mixture of THF/EtOH 1:1 (15 mL) and a 1 M solution of NaOH (2.5 mmol) was 
added dropwise while stirring. The reaction mixture was heated at reflux for 5 h. After 
completion, the solvent was evaporated under reduced pressure; the aqueous phase was washed 
with CHCl3 (1 x 5 mL), acidified with 3 M HCl and then extracted with EtOAc (3 x 7 mL). The 
organic layers were washed with brine, dried over anhydrous Na2SO4 and then concentrated in 
vacuo. The resulting solid was washed with cool hexane (3 mL). Procedure A2. The appropriate 
methyl ester derivative (1 mmol) was treated with LiOH·H2O (3.0 mmol) in a mixture of THF–
H2O 2:1 (15 mL) at room temperature for 2 h. After completion, the solution was acidified with 
1 M HCl and then extracted with EtOAc (3 x 7 mL). The organic layers were washed with brine, 
dried over anhydrous Na2SO4 and then concentrated in vacuo.
11,12 
General Procedure B. The suitable aromatic ester (1 mmol), the appropriate phenylboronic 
acid (1.3 mmol) and bis(triphenylphosphine)palladium(II) dichloride (5% mol) were dissolved in 
dry 1,4-dioxane (10 mL), under N2 atmosphere. A 2 M Na2CO3 solution (2 mmol) was added 
and the resulting mixture was stirred overnight at 90 °C. After completion, the solution was 
cooled to room temperature and then filtered on a celite pad. The filtrate was diluted with H2O 
and extracted with EtOAc (3 x 4 mL). The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo.11,12 
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General Procedure C. Methyl 5-boronofuran-2-carboxylate (17, 1.3 mmol), the appropriate 
bromo-derivatives (1.0 mmol) and bis-(triphenylphosphine)palladium(II) dichloride (5% mol) 
were dissolved in dry 1,4-dioxane (10 mL), under N2 atmosphere. A 2 M Na2CO3 solution (2 
mmol) was then added, and the resulting mixture was stirred in a microwave synthesizer 
(Biotage® Initiator Classic) for 1 h at 60 °C. After completion, the solution was cooled to room 
temperature and filtered on a celite pad. The filtrate was diluted with H2O and extracted with 
EtOAc (3 x 4 mL). The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.11,12 
General procedure D. The appropriate aromatic carboxylic acid (1 mmol) was dissolved in 
MeOH (4.8 mL) before concentrated H2SO4 (0.7 mL) was added dropwise while stirring. The 
reaction mixture was refluxed for 24 h. After completion, the solution was cooled to room 
temperature and MeOH was removed in vacuo; the aqueous phase was treated with a saturated 
solution of NaHCO3 to ensure neutral-basic pH and then extracted with EtOAc (3 x 4 mL). The 
combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.24 
5-(3-Chlorophenyl)furan-2-carboxylic acid (2). Procedure A1. Starting compound: methyl 
5-(3-chlorophenyl)furan-2-carboxylate (50 mg, 0.21 mmol, 12). Light brown solid. Yield: 42 
mg, 0.19 mmol, 89%. Mp: 187 °C (dec.). TLC (DCM–MeOH 8:2): Rf = 0.27. 1H NMR (300 
MHz, DMSO-d6) δ (ppm): 7.76 (t, J = 1.7 Hz, 1H, H7), 7.67 (d, J =7.7, 1H, H11), 7.44 (t, J = 7.7 
Hz, 1H, H10), 7.33 (d, J =7.7, 1H, H9), 7.06 (d, J = 3.4 Hz, 1H, H3), 6.88 (s, 1H, H4). 
13C NMR 
(75 MHz, DMSO-d6) δ: 160.72, 160.45, 160.36, 151.98, 134.45, 132.97, 131.56, 128.09, 123.92, 
122.95, 109.29. FT-IR (KBr) ν cm-1: 3412, 2961, 2920, 2851, 1674, 1660, 1602, 1525, 1461, 
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1420, 1384, 1305, 1278, 776. HRMS (ESI-QOrbitrap) m/z: calcd. for C11H7ClO3 [M-H]
-, 
221.0011. Found 221.0022. 
5-(3-Hydroxyphenyl)furan-2-carboxylic acid (3). Procedure A1. Starting compound: methyl 
5-(3-hydroxyphenyl)furan-2-carboxylate (55 mg, 0.25 mmol, 13). White solid. Yield: 48 mg, 
0.24 mmol, 94%. Mp: 170 °C. TLC (DCM–MeOH 7:3): Rf = 0.40. 1H NMR (300 MHz, DMSO-
d6) δ (ppm): 13.10-13.00 (bs exch. D2O, 1H, COOH), 9.80-9.60 (bs exch. D2O, 1H, OH), 7.26 
(d, J = 3.4 Hz, 1H, H3), 7.18-7.06 (m, 3H, H7,10,11), 7.04 (d, J = 3.4 Hz, 1H, H4), 6.77 (dt, J = 7.3, 
2.1 Hz, 1H, H9). 
13C NMR (75 MHz, DMSO-d6) δ (ppm): 159.72, 158.30, 156.76, 144.46, 
130.77, 130.75, 122.18, 116.55, 115.83, 111.33, 108.19. FT-IR (KBr) ν cm-1: 3401, 2919, 1675, 
1649, 1582, 1533, 1470, 1418, 1309, 1298, 1284, 1200, 1160, 1025, 954, 852, 799, 785. HRMS 
(ESI-QOrbitrap) m/z: calcd for C11H9O4 [M+H]
+, 205.0495. Found 205.0499.  
5-(m-Tolyl)furan-2-carboxylic acid (4). Procedure A1. Starting compound: methyl 5-(m-
tolyl)furan-2-carboxylate (48 mg, 0.22 mmol, 18). Brown solid. Yield: 39 mg, 0.19 mmol, 86%. 
Mp: 147 °C. TLC (DCM–MeOH 8:2): Rf = 0.35. 1H NMR (300 MHz, DMSO-d6) δ (ppm): 13.07 
(bs exch. D2O, 1H, COOH), 7.62-7.56 (m, 2H, H7,11), 7.34 (t, J = 7.7 Hz, 1H, H10), 7.29 (d, J = 
3.7 Hz, 1H, H3), 7.19 (d, J = 7.7 Hz, 1H, H9), 7.09 (d, J = 3.7 Hz, 1H, H4), 2.35 (s, 3H, CH3). 
13C 
NMR (75 MHz, DMSO-d6) δ (ppm): 159.71, 156.85, 144.50, 138.82, 130.08, 129.59, 129.38, 
125.23, 122.09, 120.29, 108.24, 21.35. FT-IR (KBr) ν cm-1: 3435, 2918, 2666, 2611, 2573, 1674, 
1609, 1593, 1573, 1518, 1472, 1421, 1366, 1312, 1275, 1218, 1164, 1024, 788, 760. HRMS 
(ESI-QOrbitrap) m/z: calcd for C12H10O3 [M+H]
+, 203.0703. Found 203.0702. 
5-(3-Aminophenyl)furan-2-carboxylic acid (5). Procedure A1. Starting compound: methyl 5-
(3-aminophenyl)furan-2-carboxylate (40 mg, 0.18 mmol, 22). Yellow solid. Yield: 33 mg, 0.16 
mmol, 89%. Mp: 225 °C (dec.). TLC (DCM–MeOH 7:3): Rf = 0.33. 1H-NMR (300 MHz, 
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DMSO-d6) δ (ppm): 7.25 (d, J = 3.7 Hz, 1H, H3), 7.10 (t, J = 7.9 Hz, 1H, H10), 6.99 (t, J = 2.0 
Hz, 1H, H7), 6.92 (m, 1H, H11), 6.91 (d, J = 3.7 Hz, 1H, H4), 6.56 (ddd, J = 7.9, 2.0, 1.0 Hz, 1H, 
H9). 
13C NMR (75 MHz, DMSO-d6) δ (ppm): 159.79, 157.61, 149.65, 144.21, 130.12, 129.95, 
120.11, 115.09, 112.75, 109.69, 107.49. FT-IR (KBr) ν cm-1: 3439, 3350, 3241, 3122, 3056, 
2961, 2920, 2850, 1682, 1621, 1604, 1573, 1525, 1490, 1471, 1376, 1257, 959, 949, 803, 781. 
HRMS (ESI-QOrbitrap) m/z: calcd C11H9NO3 [M-H]
-, 202.0510. Found 202.0512. 
5-(3-Carbamoylphenyl)furan-2-carboxylic acid (6). Procedure A1. Starting compound: 
methyl 5-(3-carbamoylphenyl)furan-2-carboxylate (45 mg, 0.18 mmol, 15). White solid. Yield: 
34 mg, 0.15 mmol, 81%. Mp: 250 °C. TLC (DCM–MeOH 7:3): Rf = 0.29. 1H NMR (300 MHz, 
DMSO-d6) δ (ppm): 13.10-13.00 (bs exch. D2O, 1H, COOH), 8.27 (s, 1H, H7), 8.11 (bs exch. 
D2O, 1H, NH2), 7.92 (d, J = 7.8 Hz, 1H, H9), 7.86 (d, J = 7.8 Hz, 1H, H11), 7.55 (t, J = 7.8 Hz, 
1H, H10), 7.49 (bs exch. D2O, 1H, NH2), 7.33 (d, J = 3.6 Hz, 1H, H3), 7.19 (d, J = 3.6 Hz, 1H, 
H4). 
13C NMR (75 MHz, DMSO-d6) δ (ppm): 167.68, 159.69, 156.09, 144.93, 135.59, 129.69, 
129.56, 128.19, 127.39, 123.90, 120.26, 108.92. FT-IR (KBr) ν cm-1: 3451, 3188, 2920, 2649, 
2527, 1682, 1598, 1518, 1449, 1403, 1299, 1273, 1160, 1025, 958, 942, 795, 761. HRMS (ESI-
QOrbitrap) m/z: calcd for C12H10NO4 [M+H]
+, 232.0604. Found 232.0614. 
5-(3-(Methylcarbamoyl)phenyl)furan-2-carboxylic acid (7). Procedure A2. Starting 
compound: methyl 5-(3-(methylcarbamoyl)phenyl)furan-2-carboxylate (41 mg, 0.17 mmol, 19). 
Yellow solid. Yield: 87%. Mp: 159 °C. TLC (DCM–MeOH 7:3): Rf = 0.32. 1H NMR (300 MHz, 
DMSO-d6) δ (ppm): 8.58 (q exch. D2O, J = 4.5 Hz, 1H, NH), 8.22 (t, J = 1.7 Hz, 1H, H7), 7.92 
(dt, J = 7.8, 1.7 Hz, 1H, H9), 7.82 (dt, J = 7.8, 1.7 Hz, 1H, H11), 7.55 (t, J = 7.8 Hz, 1H, H10), 
7.33 (d, J = 3.6 Hz, 1H, H3), 7.18 (d, J = 3.6 Hz, 1H, H4), 2.80 (d, J = 4.5 Hz, 3H, CH3). 
13C 
NMR (75 MHz, DMSO-d6) δ (ppm): 166.54, 159.67, 156.10, 144.87, 135.85, 129.70, 129.62, 
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127.83, 127.28, 123.42, 120.31, 108.95, 26.73. FT-IR (KBr) ν cm-1: 3324, 3116, 3066, 2925, 
1718, 1692, 1649, 1584, 1549, 1521, 1481, 1468, 1423, 1407, 1310, 1260, 1220, 1158, 1026, 
803, 760. HRMS (ESI-QOrbitrap) m/z: calcd for C13H11NO4 [M+H]
+, 246.0761. Found 
246.0761. 
5-(3-Sulfamoylphenyl)furan-2-carboxylic acid (8). Procedure A1. Starting compound: 
methyl 5-(3-sulfamoylphenyl)furan-2-carboxylate (50 mg, 0.18 mmol, 20). Yellow solid. Yield: 
40 mg, 0.15 mmol, 84%. Mp: 261 °C (dec.). TLC (DCM–MeOH 7:3): Rf = 0.24. 1H NMR (300 
MHz, DMSO-d6) δ (ppm): 13.22 (bs exch. D2O, 1H, COOH), 8.21 (t, J = 1.8 Hz, 1H, H7), 8.03 
(dt, J = 7.9, 1.8 Hz, 1H, H11), 7.81 (dt, J = 7.9, 1.8 Hz, 1H, H9), 7.67 (t, J = 7.9 Hz, 1H, H10), 
7.48 (s exch. D2O, 2H, NH2), 7.35 (d, J = 3.7 Hz, 1H, H3), 7.26 (d, J = 3.7 Hz, 1H, H4). 
13C 
NMR (75 MHz, DMSO-d6) δ (ppm): 170.43, 159.61, 155.14, 145.55, 145.25, 130.28, 130.23, 
128.10, 126.17, 121.31, 120.28, 109.67. FT-IR (KBr) ν cm-1: 3340, 3252, 2919, 2844, 2671, 
2573, 1669, 1692, 1518, 1458, 1424, 1341, 1322, 1266, 1220, 1161, 1028, 890, 793, 762. HRMS 
(ESI-QOrbitrap) m/z: calcd for C12H8O5 [M-H]
-, 266.0129. Found 266.0129. 
5-(3-Carboxyphenyl)furan-2-carboxylic acid (9). Procedure A1. Starting compound: methyl 
5-(3-(methoxycarbonyl)phenyl)furan-2-carboxylate (60 mg, 0.23 mmol, 21). White solid. Yield: 
50 mg, 0.20 mmol, 88%. Mp > 300 °C. TLC (DCM–MeOH 8:2): Rf = 0.26. 1H NMR (300 MHz, 
DMSO-d6) δ (ppm): 13.20 (2H, bs exch. D2O, 2H, COOH), 8.30 (s, 1H, H7), 8.04 (d, J = 7.8, 1H, 
H9), 7.92 (d, J = 7.8, 1H, H11), 7.60 (t, J = 7.8 Hz, 1H, H10), 7.32 (d, J = 3.6 Hz, 1H, H3), 7.25 (d, 
J = 3.6 Hz, 1H, H4). 
13C NMR (75 MHz, DMSO-d6) δ (ppm): 167.2, 159.7, 155.6, 145.0, 132.2, 
129.9, 129.8, 129.1, 125.2, 120.2, 119.2. FT-IR (KBr) ν cm-1: 3435, 2966, 2917, 2851, 2661, 
2546, 1681, 1612, 1521, 1455, 1420, 1298, 1165, 1030, 804 761. HRMS (ESI-QOrbitrap) m/z: 
calcd for C12H8O5 [M-H]
-, 231.0299. Found 231.0301. 
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5-(3-Cyanophenyl)furan-2-carboxylic acid (10). Procedure A2. Starting compound: methyl 
5-(3-cyanophenyl)furan-2-carboxylate (46 mg, 0.20 mmol, 16). White solid. Yield: 38 mg, 0.18 
mmol, 87%. Mp: 260 °C (dec.). TLC (DCM–MeOH 8:2): Rf = 0.20. 1H NMR (300 MHz, 
DMSO-d6) δ (ppm): 13.30 (bs exch D2O, 1H, COOH), 8.28 (s, 1H, H7), 8.10 (d, J = 7.8 Hz, 1H, 
H9); 7.80 (d, J = 7.8 Hz, 1H, H11), 7.69 (t, J = 7.8 Hz, 1H, H10), 7.34 (s, 2H, H3,4). 
13C NMR (75 
MHz, DMSO-d6) δ (ppm): 159.61, 154.33, 145.60, 132.55, 130.87, 130.75, 129.00, 128.36, 
120.12, 118.77, 112.81, 110.22. FT-IR (KBr) ν cm-1: 3112, 2915, 2850, 2666, 2576, 2231, 1710, 
1686, 1608, 1572, 1519, 1475, 1436, 1318, 1289, 1232, 1174, 1033, 997, 819, 801, 761, 582. 
HRMS (ESI-QOrbitrap) m/z: calcd for C12H7NO3 [M-H]
-, 212.0353. Found 212.0351. 
5-(3-cyanophenyl)furan-2-carboxamide (11). HATU (178 mg, 0.47 mmol) and N,N-
diisopropylethylamine (0.32 mL, 1.9 mmol) were added to a solution of 5-(3-cyanophenyl)furan-
2-carboxylic acid (100 mg, 0.47 mmol, 10) in DMF (2.50 mL), and the resulting mixture was 
stirred for 30 min at room temperature. Then, NH4Cl (75 mg, 1.4 mmol) was added, and the 
stirring was continued for 2 more hours. After completion, the reaction was neutralized with 1 M 
HCl and partitioned between EtOAc and H2O. The organic layer was washed three times with 
cold H2O, dried over anhydrous Na2SO4 and concentrated in vacuo.
25 The crude product was 
purified by crystallization from DCM/hexane to afford an off-white solid. Yield: 32 mg, 0.15 
mmol, 32%. Mp: 202 °C. TLC (DCM–MeOH 95:5): Rf = 0.27. 1H-NMR (300 MHz, DMSO-d6) 
δ (ppm): 8.45 (t, J = 1.7 Hz, 1H, H7), 8.21 (d, J = 7.8 Hz, 1H, H11), 8.08 (bs exch. D2O, 1H, NH), 
7.80 (d, J = 7.8, 1H, H9), 7.65 (t, J = 7.8 Hz, 1H, H10), 7.52 (bs exch. D2O, 1H, NH), 7.25 (d, J = 
3.6 Hz, 1H, H3), 7.15 (d, J = 3.6 Hz, 1H, H4). 
13C NMR (75 MHz, DMSO-d6) δ (ppm): 159.51, 
152.57, 148.48, 132.29, 131.06, 130.62, 129.01, 128.15, 118.96, 116.18, 112.66, 109.92. FT-IR 
(KBr) ν cm-1: 3474, 3167, 2962, 2923, 2852, 2225, 1697, 1614, 1535, 1518, 1470, 1425, 1395, 
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1261, 1099, 1037, 958, 903, 893, 798. HRMS (ESI-QOrbitrap) m/z: calcd for C12H8N2O2 
[M+H]+, 213.0659. Found 213.0659. 
Methyl 5-bromofuran-2-carboxylate (12). Procedure D. Starting compound 5-bromo-2-
furoic acid (500 mg, 2.6 mmol). White solid. Yield: 480 mg, 2.3 mmol, 89%. Mp: 64 °C. TLC 
(cyclohexane–EtOAc 8:2): Rf = 0.59. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.12 (d, J = 3.5 Hz, 
1H, H3), 6.45 (d, J = 3.5 Hz, 1H, H4), 3.89 (s, 3H, CH3). 
Methyl 5-(3-chlorophenyl)furan-2-carboxylate (13). Procedure B. Starting compounds: 
methyl 5-bromofuran-2-carboxylate (400 mg, 2.0 mmol, 12) and (3-chlorophenyl)boronic acid 
(407 mg, 2.6 mmol). The crude was purified by flash column chromatography (cyclohexane–
EtOAc 8:2) to give the desired product as a white solid. Yield: 321 mg, 1.4 mmol, 68%. Mp: 76 
°C. TLC (cyclohexane– EtOAc 8:2): Rf = 0.53. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.76 (s, 
1H, H7), 7.64 (d, J = 7.3 Hz, 1H, H11), 7.40 – 7.13 (m, 3H, H3,9,10), 6.75 (d, J = 3.6 Hz, 1H, H4), 
3.92 (s, 3H, CH3). 
Methyl 5-(3-hydroxyphenyl)furan-2-carboxylate (14). Procedure B. Starting compounds: 
methyl 5-bromofuran-2-carboxylate (400 mg, 2.0 mmol, 12) and (3-hydroxyphenyl)boronic acid 
(359 mg, 2.6 mmol). The crude was purified by flash column chromatography (cyclohexane–
EtOAc 8:2) to give the desired product as a white solid. Yield: 135 mg, 0.62 mmol, 31%. Mp: 
149 °C. TLC (cyclohexane–EtOAc 8:2): Rf = 0.23. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.51 – 
7.10 (m, 4H, H3,7,10,11), 6.85 (d, J = 7.6 Hz, 1H, H9), 6.72 (d, J = 3.6 Hz, 1H, H4), 5.34 (bs exch. 
D2O, 1H, OH), 3.92 (s, 3H, CH3). 
Methyl 5-(3-carbamoylphenyl)furan-2-carboxylate (15). Procedure B. Starting compounds: 
methyl 5-bromofuran-2-carboxylate (400 mg, 2.0 mmol, 12) and (3-carbamoylphenyl)boronic 
acid (429 mg, 2.6 mol). The crude was purified by flash column chromatography (DCM–EtOAc 
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7:3) to give the desired product as a white solid. Yield: 123 mg, 0.5 mmol, 25%. Mp: 192 °C. 
TLC (cyclohexane–EtOAc 4:6): Rf = 0.24. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.22 (t, J = 1.4 
Hz, 1H, H7), 7.94 (dt, J = 7.8, 1.4 Hz, 1H, H9), 7.79 (dt, J = 7.8, 1.4 Hz, 1H, H10), 7.52 (t, J = 7.8 
Hz, 1H, H11), 7.26 (d partially hidden by solvent peak, J = 3.6 Hz, 1H, H3), 6.83 (d, J = 3.6 Hz, 
1H, H4), 6.20 (bs exch. D2O, 1H, NH), 5.66 (bs exch. D2O, 1H, NH), 3.93 (s, 3H, CH3). 
Methyl 5-(3-cyanophenyl)furan-2-carboxylate (16). Procedure B. Starting compounds: 
methyl 5-bromofuran-2-carboxylate (400 mg, 2.0 mmol, 12) and (3-cyanophenyl)boronic acid 
(382 mg, 2.6 mmol). The crude was purified by flash column chromatography (cyclohexane–
EtOAc 8:2) to give the desired product as a white solid. Yield: 345 mg, 1.5 mmol, 75%. Mp: 149 
°C. TLC (cyclohexane–EtOAc 8:2): Rf = 0.33. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.06 (s, 
1H, H7), 8.00 (d, J = 7.8 Hz, 1H, H11), 7.62 (d, J = 7.8 Hz, 1H, H9), 7.54 (t, J = 7.8 Hz, 1H, H10), 
7.26 (d partially hidden by solvent peak, J = 3.6 Hz, 1H, H3), 6.83 (d, J = 3.6 Hz, 1H, H4), 3.94 
(s, 3H, CH3). 
(5-(Methoxycarbonyl)furan-2-yl)boronic acid (17). Isopropylmagnesium chloride (2 M in 
THF, 2.4 mmol) was added to a solution of bis[2-(N,N-dimethylamino)ethyl] ether (62 mg, 2.4 
mmol) in THF (10 mL) under N2 atmosphere. The resulting mixture was stirred for 20 min at 10-
15 °C, before methyl 5-bromofuran-2-carboxylate (400 mg, 2.0 mmol, 12) was added; the 
stirring was continued at room temperature for 30 min. Then, trimethyl borate (416 mg, 4.0 
mmol) was added at 0 °C and the reaction mixture was stirred for 10 min. After quenching with 
diluted 1 M HCl, the reaction was extracted with EtOAc (3 x 4 mL) and the organic layers were 
washed with brine, dried over anhydrous Na2SO4 and evaporated in vacuo. The resulting brown 
solid was purified via crystallization from hexane and EtOAc, to afford the desired product as a 
beige solid. Yield: 255 mg, 1.5 mmol, 75%. Mp: 128 °C (dec.). TLC (cyclohexane–EtOAc 8:2): 
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Rf = 0.54. 
1H-NMR (300 MHz, CDCl3) δ (ppm): 7.19 (d, J = 3.5 Hz, 1H, H3), 7.08 (d, J = 3.5 
Hz, 1H, H4), 3.91 (s, 3H, CH3).
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Methyl 5-(m-tolyl)furan-2-carboxylate (18). Procedure C. Starting compounds: (5-
(methoxycarbonyl)furan-2-yl)boronic acid (221 mg, 1.3 mmol, 17) and 1-bromo-3-
methylbenzene (171 mg, 1.0 mol). The crude was purified by flash column chromatography 
(cyclohexane–EtOAc 8:2) to give the desired product as a white solid. Yield: 112 mg, 0.52 
mmol, 52%. Mp: 76 °C. TLC (cyclohexane–EtOAc 8:2): Rf = 0.73. 1H-NMR (300 MHz, CDCl3) 
δ (ppm): 7.62 (s, 1H, H7), 7.57 (d, J = 7.7 Hz, 1H, H11), 7.30 (t, J = 7.7 Hz, 1H, H10), 7.24 (d, J = 
3.6 Hz, 1H, H3), 7.16 (d, J = 7.7 Hz, 1H, H9), 6.72 (d, J = 3.6 Hz, 1H, H4), 3.92 (s, 3H, OCH3), 
2.40 (s, 3H, CH3). 
Methyl 5-(3-(methylcarbamoyl)phenyl)furan-2-carboxylate (19). Procedure C. Starting 
compounds: (5-(methoxycarbonyl)furan-2-yl)boronic acid (221 mg, 1.3 mmol, 17) and 3-bromo-
N-methylbenzamide (213 mg, 1.0 mmol, 24). The crude was purified by flash column 
chromatography (cyclohexane–EtOAc 5:5) to give the desired product as a yellow solid. Yield: 
83 mg, 0.32 mmol, 32%. Mp: 76 °C. TLC (cyclohexane–EtOAc 5:5): Rf = 0.15. 1H-NMR (300 
MHz, CDCl3) δ (ppm): 8.11 (s, 1H, H7), 7.86 (d, J = 7.8 Hz, 1H, H11), 7.73 (d, J = 7.8 Hz, 1H, 
H9), 7.45 (t, J = 7.8 Hz, 1H, H10), 7.23 (d, J = 3.6 Hz, 1H, H3), 6.78 (d, J = 3.6 Hz, 1H, H4), 6.45 
(bs exch. D2O, 1H, NH), 3.91 (s, 3H, OCH3), 3.03 (d, J = 4.6 Hz, 3H, NHCH3). 
Methyl 5-(3-sulfamoylphenyl)furan-2-carboxylate (20). Procedure C. Starting compounds: 
(5-(methoxycarbonyl)furan-2-yl)boronic acid (221 mg, 1.3 mmol, 17) and 3-
bromobenzenesulfonamide (237 mg, 1.0 mmol). The crude was purified by flash column 
chromatography (cyclohexane–EtOAc 8:2) to give the desired product as a white solid. Yield: 
217 mg, 0.77 mmol, 77%. Mp: 238 °C. TLC (cyclohexane–EtOAc 5:5): Rf = 0.38. 1H-NMR 
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(300 MHz, Acetone-d6) δ (ppm): 8.32 (t, J = 1.8 Hz, 1H, H7), 8.06 (ddd, J = 7.8, 1.8, 1.1 Hz, 1H, 
H9), 7.91 (ddd, J = 7.8, 1.8, 1.1 Hz, 1H, H11), 7.69 (t, J = 7.8 Hz, 1H, H10), 7.36 (d, J = 3.7 Hz, 
1H, H3), 7.21 (d, J = 3.7 Hz, 1H, H4), 6.73 (bs exch. D2O, 2H, SO2NH2), 3.90 (s, 3H, CH3). 
Methyl 5-(3-(methoxycarbonyl)phenyl)furan-2-carboxylate (21). Procedure C. Starting 
compounds: (5-(methoxycarbonyl)furan-2-yl)boronic acid (221 mg, 1.3 mmol, 17) and methyl 3-
bromobenzoate (214 mg, 1.0 mmol). The crude was purified by flash column chromatography 
(cyclohexane–EtOAc 8:2) to give the desired product as a white solid. Yield: 125 mg, 0.48 
mmol, 48%. Mp: 115 °C. TLC (cyclohexane–EtOAc 8:2): Rf = 0.51. 1H-NMR (300 MHz, 
CDCl3) δ (ppm): 8.42 (s, 1H, H7), 8.04-7.98 (m, 2H, H9,11), 7.52 (t, J = 7.8 Hz, 1H, H10), 7.28 (d 
partially hidden by solvent peak, J = 3.6 Hz, 1H, H3), 6.84 (d, J = 3.6 Hz, 1H, H4), 3.96 (s, 3H, 
CH3), 3.93 (s, 3H, CH3). 
Methyl 5-(3-aminophenyl)furan-2-carboxylate (22). To a solution of methyl 5-(3-
nitrophenyl)furan-2-carboxylate (232 mg, 1.0 mmol, 23) in EtOAc (4 mL), SnCl2 (57 mg, 0.3 
mmol) was added and the mixture was refluxed for 5 h. After quenching by addition of a 
saturated solution of NaHCO3 until pH 7-8, the precipitated tin salts were eliminated by 
filtration, and the aqueous phase was extracted with EtOAc (3 x 4 mL). The organic layer was 
dried over Na2SO4, filtered and evaporated under vacuum. The crude residue was purified by 
flash column chromatography (cyclohexane–EtOAc 8:2) to provide the desired compound as a 
white solid. Yield: 165 mg, 0.76 mmol, 76%. Mp: 215 °C (dec.). TLC (cyclohexane–EtOAc 
8:2): Rf = 0.45. 
1H NMR (300 MHz, DMSO-d6) δ (ppm): 7.36 (d, J = 3.7 Hz, 1H, H3), 7.09 (t, J 
= 7.8 Hz, 1H, H11), 7.00 (t, J = 2.0 Hz, 1H, H7), 6.97 (d, J = 3.7 Hz, 1H, H4), 6.94 (d, J = 7.8 Hz, 
1H, H9), 6.57 (dd, J = 7.8, 2.0 Hz, 1H, H9), 5.31 (bs exch. D2O, 2H, NH2), 3.81 (s, 3H, CH3).
26 
 36 
Methyl 5-(3-nitrophenyl)furan-2-carboxylate (23). Procedure D. Starting compound: 5-(3-
nitrophenyl)furan-2-carboxylic acid (233 mg, 1.0 mmol). Light yellow solid. Yield: 215 mg, 0.87 
mmol, 87%. Mp= 143 °C. TLC (cyclohexane–EtOAc 8:2) Rf = 0.28. 1H NMR (300 MHz, 
CDCl3) δ (ppm): 8.59 (t, J = 2.0 Hz, 1H, H7), 8.20 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H, H11), 8.11 (ddd, 
J = 8.0, 2.0, 1.0 Hz, 1H, H9), 7.62 (t, J = 8.0 Hz, 1H, H10), 7.29 (d, J = 3.6 Hz, 1H, H3), 6.91 (d, J 
= 3.6 Hz, 1H, H4), 3.95 (s, 3H, CH3). 
3-Bromo-N-methylbenzamide (24). To a solution of 3-bromobenzoic acid (200 mg, 1.0 
mmol) in THF (4 mL), HATU (570 mg, 1.5 mmol) and N,N-diisopropylethylamine (259 mg, 2.0 
mmol) were added at 0 °C. The reaction mixture was stirred for 30 min at room temperature. 
Methylamine (2 M in THF, 2.0 mmol) was added and the reaction was stirred for 18 h. After 
completion, the mixture was extracted with EtOAc (3 x 4 mL). The organic phase was dried over 
Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified by 
flash column chromatography (DCM–MeOH 97:3) to afford a grey solid. Yield: 151 mg, 0.71 
mmol, 71%. Mp: 91 °C. TLC (DCM–MeOH 97:3): Rf = 0.33. 1H-NMR (300 MHz, CDCl3) δ 
(ppm): 7.89 (s, 1H, H2), 7.66 (d, J = 7.8 Hz, 1H, H6), 7.56 (d, J = 7.8 Hz, 1H, H4), 7.23 (t, J = 7.8 
Hz, 1H, H5), 6.80 (bs exch. D2O, 1H, NH), 2.95 (d, J = 4.7 Hz, 3H, CH3).
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Production and purification of MbtI for crystallization trials 
Escherichia coli BL21 cells were transformed with a pET-28a plasmid (GenScript, 
Piscataway, NJ, USA), bearing a codon-optimized open reading frame for MbtI. Two 
transformed colonies were added to a starter medium (9.2 mL 2YT medium pH 7.0, 200 μL of 
40% glucose, 100 μL of 1 M MgSO4, 500 μL of 20X NPS buffer, 20 μL of 50 mg/mL 
kanamycin) and stirred at 37 °C and 180 rpm for 7 h. Then, sterile 5 L Erlenmeyer flasks were 
filled with 1 L of 2YT medium pH 7.0, 50 mL of auto-induction supplement (0.5% glycerol, 
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0.05% glucose, 0.2% α-lactose, 25 mM (NH4)2SO4, 50 mM KH2PO4, 50 mM Na2HPO4, 1 mM 
MgSO4) and 2 mL of 50 mg/mL kanamycin; 1 mL of the starter suspension was added to each 
flask and the culture was stirred at 180 rpm for 4 h at 37 °C, and 12 h at 25 °C. 
After centrifugation, the cell pellet was re-suspended using 50 mL of IMAC A solution (25 
mM Tris∙HCl pH 8.5, 300 mM NaCl, 25 mM imidazole), with the addition of 50 μL of 
Benzonase® Nuclease (Sigma-Aldrich) and a tablet of EDTA-free protease inhibitor complex 
(cOmplete™, Sigma-Aldrich). Then, the cells were lysed with a CF2 cell disruptor (Constant 
Systems Ltd., Daventry, UK) and centrifuged. The supernatant was charged on a 1 mL 
HisTrap™ High Performance column (GE Healthcare, Chicago, IL, USA) and eluted with a 
gradient obtained by mixing IMAC A and IMAC B (25 mM Tris∙HCl pH 8.5, 300 mM NaCl, 
400 mM imidazole) solutions. Then, TEV protease (200 µL of a 10 mg/mL solution) was added 
to the protein solution to cleave the His-tag, along with 5 µL of 1 M DTT (final concentration ≈ 
100 mM). The resulting mixture was dialyzed overnight at 4 °C in a solution containing 25 mM 
Hepes·NaOH pH 8.0, 150 mM NaCl, 0.5 mM DTT. Subsequently, 40 mM imidazole was added 
to the dialyzed protein, and the solution was loaded on a BioRad column charged with Ni-NTA 
resin, to remove the His-tag. The column was washed with IMAC B, and the protein was 
concentrated to about 1 mL, using 20 mL Vivaspin™ 15R Centrifugal Concentrators equipped 
with a 10000 Da cut-off filter (Sartorius, Göttingen, Germany). The supernatant was loaded on a 
HiLoad 16/600 Superdex 200 exclusion chromatography column (GE Healthcare), previously 
equilibrated with the eluent solution (25 mM Hepes·NaOH pH 8.0, 150 mM NaCl, 1% glycerol). 
The fractions containing the protein were collected and concentrated to allow the obtainment of 
the final purified protein solution at about 20 mg/mL concentration (calculated with a 
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NanoDrop™ 1000, ThermoFisher Scientific); the samples were flash-frozen with liquid nitrogen 
and stored at -80 °C. 
Crystallization of MbtI-10, MbtI-Mg2+ and MbtI-Ba2+ complexes 
The crystallization experiments were performed at 4 °C by the sitting drop vapor diffusion 
technique in 96-well plates, according to established protocols at the Crystallography Core 
Facility of the Institut Pasteur.28 The trials were set up with a Mosquito® crystal Nanoliter 
Protein Crystallization Robot (TTP Labtech, Melbourne, UK); the plates were stored in a Rock 
Imager® 1000 (Formulatrix, Bedford, MA, USA) and visually checked through the dedicated 
image repository, following a specific timetable. The drops were obtained by mixing an equal 
amount of protein and reservoir solutions to a final volume of 400 nL; the reservoir contained 
150 μL of the precipitant mixture. 
A solution of freshly purified MbtI was concentrated to 20 mg/mL in the gel filtration buffer 
(25 mM Hepes·NaOH pH 8.0, 150 mM NaCl, 1% glycerol); the sodium salt of 10, dissolved in 
H2O, was added to the protein to a final concentration of 5 mM and incubated at 4 °C overnight. 
Prism-shaped crystals of up to 320 × 160 × 30 μm grew within two weeks in the presence of 
20% PEG 3350 and 0.2 M solutions of different sodium salts, among which sodium tartrate 
provided the best results. The previously described protocol was also applied for the obtainment 
of the MbtI-Mg2+ and MbtI-Ba2+ crystals. MbtI-Mg2+ crystals (tabular, maximum side length: 
160 μm) grew within two weeks in the presence of 1.75 M MgSO4 and 0.1 M MES pH 6.5, 
while MbtI-Ba2+ crystals (prism, maximum side length: 270 μm) grew within three weeks in the 
presence of 5 mM chorismic acid barium salt, 0.04 M KH2PO4, 16% PEG 8000 and 16% 
glycerol. The crystals were harvested with CryoLoops (Hampton Research, Aliso Viejo, CA, 
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USA), cryoprotected in a 1:1 mixture of paraffin and parathon oil (Hampton Research) and flash-
frozen by rapid immersion in liquid nitrogen. 
Data collection and structure solution 
Diffraction data were acquired at the SOLEIL Synchrotron (Saint-Aubin, France) on the 
beamlines PROXIMA-1 for MbtI-10 complex and PROXIMA-2A for MbtI-Mg2+ and MbtI-Ba2+, 
from crystals maintained at 100 K. The data were processed, scaled, and analyzed using XDSME 
and autoPROC.29,30 The structures were solved with the Molecular Replacement (MR) method 
through the program PHASER,31 available in the CCP4 suite,32 using as model the PDB-
deposited structure 3RV7.20 The geometrical restraints for the inhibitor 10 were generated with 
the Grade server (http://grade.globalphasing.org), while restraints for the salicylate were 
obtained from AceDRG.33 All rebuilding and adjustments of the models were performed with 
COOT.34 The refinement was carried out with BUSTER,35 applying local structure similarity 
restraints for non-crystallography symmetry (NCS) and a Translation-Libration-Screw (TLS) 
model. The final validation was performed with MOLPROBITY and PHENIX.36,37 Data 
collection, refinement, and model statistics are summarized in Table 2. Graphical representations 
were rendered with Pymol.38 
 
Table 2. Data collection, refinement, and model statistics of MbtI-10, MbtI-Mg2+ and MbtI-Ba2+. 
 MbtI-10 MbtI-Mg2+ MbtI-Ba2+ 
Space group P21 I422 P21 
Unit-cell parameters    
a, b, c (Å) 88.336, 111.687, 
94.998 
193.97, 193.97, 
257.03 
88.04, 116.90 
94.09 
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α, β, γ (°) 90, 92.67, 90 90, 90, 90 90, 91.60, 90 
Resolution range (Å) 111.69 – 2.09 
(2.13 – 2.09) 
154.83 – 2.11 
(2.15 – 2.11) 
43.63 – 1.80 
(1.85 – 1.80) 
Wavelength (Å) 0.97856 0.98012 0.98012 
No. unique reflections 108510 (5396) 131041 (6551) 173404 (11664) 
Multiplicity 7.0 (7.1) 27.0 (26.5) 6.8 (6.5) 
Completeness (%) 99.9 (99.9) 93.9 (85.6) 99.2 (90.3) 
Average I/σ(I) 8.0 (2.1) 17.7 (1.4) 14.6 (1.0) 
Rpim
a 0.063 (0.356) 0.028 (0.546) 0.030 (0595) 
CC(1/2) 0.990 (0.803) 0.998 (0.534) 0.999 (0.622) 
Refinement statistics    
Rwork
b 0.208  0.195  0.196  
Rfree
b 0.240  0.217  0.214  
No. of non-H atomsc    
Protein 12651 13151 13228 
Ligands 65 198 51 
Water 878 797 1351 
Average B-factorsc    
Protein 43.33 51.97 35.98 
Ligands 56.33 89.33 43.89 
Water 44.14 53.14 42.82 
Rms deviationsc    
Bonds (Å) 0.012 0.012 0.012 
Angles (°) 1.45 1.50 1.45 
Molprobity Clashscorec 3.13 2.90 1.51 
Ramachandran outliersc (%) 0.00 0.00 0.00 
Ramachandran favouredc (%) 98.98 98.34 98.80 
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Rotamer outliersc (%) 1.09 1.11 1.11 
C-beta outliersc (%) 0.00 0.00 0.00 
PDB code 6ZA4 6ZA5 6ZA6 
Data were indexed and scaled with XDSME (MbtI-Ba2+) or autoPROC (MbtI-10 and MbtI-
Mg2+), applying, in the latter case, an anisotropic resolution cut-off via STARANISO as 
implemented in autoPROC.30 aRpim=Σh[1/(/nh - 1)]1/2Σi|<Ih>Ih,i|/ΣhΣiIh,i, where Ih is the intensity 
of the unique reflection h, whereas Ii is the intensity of each of its symmetry-equivalent 
reflections. CC(1/2) according to Karplus.39 bRwork = Σ||Fo| − |Fc||/Σ|Fo|, where Fo and Fc are the 
observed and calculated structure factor amplitudes. Five percent of the reflections were reserved 
for the calculation of Rfree. 
cCalculated with phenix.validate.37 
MbtI enzymatic assays 
MbtI was produced in recombinant form and purified, as previously reported.12 The enzyme 
activity was determined by a fluorimetric assay, performed in a final volume of 400 µL at 37 °C, 
in 50 mM Hepes pH 7.5, 5 mM MgCl2, 1-2 μM MbtI. The reactions were started by the addition 
of chorismic acid and monitored using a Perkin-Elmer LS3 fluorimeter (Ex. λ = 305 nm, Em. λ = 
420 nm). Initial inhibition assays were carried out in the presence of 100 μM of each compound 
(stock solution 20 mM in DMSO) and chorismic acid at a final concentration of 50 μM. For the 
most potent inhibitors, the IC50 and Ki were determined. For IC50 determinations, the enzyme 
activity was measured at different compound concentrations, and values were calculated 
according to the Equation 1, with Origin 8 software: 
A[I] = A[0] × (1-
[I]
[I]+IC50
)  (Equation 1) 
where A[I] is the activity of the enzyme at inhibitor concentration [I] and A[0] is the activity of 
the enzyme without inhibitor. 
The Ki was determined at different substrate [S] and compound concentrations, using Equation 
2: 
v = 
Vmax[S]
[S]+Km (1+
[I]
Ki
)
  (Equation 2) 
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To verify that the compounds were not pan-assay interference compounds (PAINS), the 
inhibition was tested in the presence of 0.1 mg/mL of bovine serum albumin (BSA), or 0.01% 
(v/v) Triton X-100 to confirm that they did not act as aggregators, and with 100 mM of 1,4-
dithio-DL-threitol (DTT), to exclude an inhibition due to reaction with cysteines.40 
Minimal inhibitory concentration determinations and siderophore production assay 
The minimal inhibitory concentration MIC99 of active compounds against M. tuberculosis 
H37Rv, was determined on Middlebrook 7H11 agar solid medium, as previously reported.11 
Additionally, MIC99 against M. bovis BCG was determined in low-iron Chelated Sauton’s 
medium, by the resazurin reduction assay method (REMA).41,42 
The siderophore activity was measured by the Universal CAS liquid assay.16 M. bovis cells 
were grown in 7H9 medium, subcultured in chelated Sauton’s medium, and finally diluted to an 
OD600 of 0.01 in chelated Sauton’s containing different concentrations of compounds, in 96-well 
plates. After 15 days of incubation at 37 °C, cells were harvested. Supernatants were used to 
perform the CAS assay, while cell pellets were used for the determination of mycobactins. For 
the CAS assay, 100 µL of supernatant were mixed with 100 µL of CAS assay liquid solution in a 
96-well plate, incubated 10 min at room temperature, and absorbance was read at 630 nm. The 
siderophore units were calculated using Equation 3: 
Ar−As
Ar
× 100  (Equation 3) 
where Ar is the absorbance at 630 nm of the blank medium with CAS assay solution and As is 
the absorbance of the culture supernatants with CAS assay solution. 
For mycobactin determination, cell pellets were extracted in EtOH overnight, then 0.1 M FeCl3 
in EtOH was added until no color change was observed. The mixture was incubated at room 
temperature for 1 h. Mycobactins were extracted in CHCl3, washed with H2O and evaporated; 
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then, the residue was dissolved in MeOH. The concentration of mycobactins was determined by 
measuring the absorbance at 450 nm (1% solution of mycobactins gives an absorbance of 42.8). 
Salicylic acid determination in MbtI purified protein 
To confirm the presence of salicylic acid in complex with the purified MbtI, the protein was 
concentrated to 25 mg/mL and denatured by incubation at 95 °C for 10 min, to liberate any 
bound ligand. After 15 min of centrifugation at 12000 rpm, the supernatant was recovered and 
analyzed in UHPLC/MS. The chromatographic analysis was performed with a UHPLC apparatus 
JASCO X-LC system (Easton, MD, USA), coupled with a MS spectrometer Thermo Fisher 
Scientific LTQ XL ESI-MS/MS system. Chromatography was performed on an Acquity column 
(Waters Corporation, Milford, MA, USA), 3 µm particle size, 0.3 mL/min, gradient 10 min from 
90:10 H2O/MeCN to 100% MeCN, then 4 min in 100% MeCN. Run were also recorded at 220 
nm. The analyses were performed in full-scan from 120 and 2000 a.m.u., negative mode with 
[M-H]- at 137.11 a.m.u., and base peaks were analyzed with dependent scan method with CID = 
30 eV in order to confirm the structure. As a positive control, a solution of salicylic acid (1 
mg/mL, Sigma-Aldrich) was used, while the completely unrelated protein pantothenate kinase, 
expressed in the same E. coli strain and purified using a similar protocol to that of MbtI, was 
employed as negative control. 
Docking studies 
Compounds 10 and 11 were docked into the minimized average structure of MbtI, complexed 
with the lead I in the absence of the Mg2+ ion.11 The software Gold with ChemScore fitness 
function was used.43 The docking site was defined as the region comprising all residues that 
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stayed within 10 Å from the reference compound I. The best docking poses were taken into 
consideration and subjected to MD simulations. 
MD simulations 
All simulations were performed using AMBER 16.44 General amber force field (GAFF) 
parameters were assigned to the ligands, whereas partial charges were determined using the 
AM1-BCC method, as implemented in the Antechamber suite of AMBER 16. MD simulations 
were carried out employing the ff14SB force field at 300 K. The MbtI-10 complex was placed in 
a rectangular parallelepiped water-box and solvated with a 20 Å water cap by using the TIP3P 
explicit solvent model. Sodium ions were added as counterions in order to neutralize the system. 
Before MD simulations, two steps of minimization were performed; in the first stage, a position 
constraint of 500 kcal/(molÅ2) was applied to keep the protein fixed, thus minimizing only 
water molecules. In the second stage, the whole system was energy-minimized through 5000 
steps of steepest descent followed by conjugate gradient (CG), until a convergence of 0.05 
kcal/(mol·Å2) and imposing a harmonic potential of 10 kcal/(molÅ2) to the protein α carbon. 
Particle mesh Ewald (PME) electrostatics and periodic boundary conditions were used in the 
simulations. The time step of the simulations was 2 fs with a cutoff of 10 Å for the non-bonded 
interactions, while SHAKE algorithm was applied to keep all bonds involving hydrogen atoms 
fixed. Constant-volume periodic boundary MD simulation was carried out for the first 0.5 ns, 
during which the temperature of the system was raised from 0 to 300 K. Then, 110 ns of 
constant-pressure periodic boundary MD was performed at 300 K, using the Langevin thermostat 
in order to maintain constant the temperature of the system. A harmonic force constraint of 10 
kcal/(mol·Å2) was applied to the protein α carbons during the first 10 ns, whereas in the last 100 
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ns no restraints were applied to the system. All the obtained MD trajectories were analyzed using 
the Cpptraj program implemented in AMBER 16.44 
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